Cargando…
Genetic and Non-Genetic Determinants of Raltegravir Penetration into Cerebrospinal Fluid: A Single Arm Pharmacokinetic Study
BACKGROUND: Antiretroviral drugs vary in their central nervous system penetration, with better penetration possibly conferring neurocognitive benefit during human immunodeficiency virus (HIV) therapy. The efflux transporter gene ABCB1 is expressed in the blood-brain barrier, and an ABCB1 variant (34...
Autores principales: | Johnson, Daniel H., Sutherland, Deborah, Acosta, Edward P., Erdem, Husamettin, Richardson, Danielle, Haas, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859605/ https://www.ncbi.nlm.nih.gov/pubmed/24349334 http://dx.doi.org/10.1371/journal.pone.0082672 |
Ejemplares similares
-
Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
por: Yilmaz, Aylin, et al.
Publicado: (2009) -
Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
por: Larson, Kajal B, et al.
Publicado: (2013) -
Population Pharmacokinetics and Cerebrospinal Fluid Penetration of Fluconazole in Adults with Cryptococcal Meningitis
por: Stott, Katharine E., et al.
Publicado: (2018) -
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021) -
Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
por: Lommerse, Jos, et al.
Publicado: (2019)